CORT News and Press, Corcept Therapeutics Incorporated From 02/24/26

2026-02-24 16:26:10 ET More on Corcept Therapeutics Corcept Therapeutics: The Bad News Is Priced In; The Ovarian Cancer Upside Is Not Why Corcept Therapeutics' Relacorilant Fell Short And What It Means For The Company Corcept: Korlym Defies Generics As Relacorilant H...

NEW YORK, NY - February 21, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT T...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 2.3% to $1.75 on volume of 540,803,661 shares Interactive Strength Inc. (TRNR) rose 4.8% to $0.4287 on volume of 306,666,776 shares Theriva Biologics, Inc. (TOVX) rose 2.4% to $0.1...

2026-02-20 07:30:47 ET In January, I rated Corcept Therapeutics ( CORT ) a Hold , citing severe binary risk of its looming patent appeal against Teva Teva Pharmaceutical Industries ( TEVA ). On February 19th, the US Court of Appeals for the Federal Circuit ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the United Sta...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) rose 4.4% to $1.7852 on volume of 510,359,702 shares Interactive Strength Inc. (TRNR) rose 19.3% to $0.488 on volume of 290,201,967 shares Theriva Biologics, Inc. (TOVX) rose 9.1% to $0...

2026-02-19 11:10:48 ET More on Corcept Therapeutics Why Corcept Therapeutics' Relacorilant Fell Short And What It Means For The Company Corcept: Korlym Defies Generics As Relacorilant Hits An FDA CRL (Rating Upgrade) Corcept Therapeutics: Despite FDA Blind Side, Rela...

NEW YORK, NY - February 19, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT T...

NEW YORK, NY - February 18, 2026 ( NEWMEDIAWIRE ) -  Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Corcept Therapeutics, Inc. (“Corcept” or the “Company”) (NASDAQ: CORT). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT T...

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). ...